血清胸苷激酶1在体检中老年人群肿瘤普筛中的研究

目的研究中老年(45岁以上)体检人群,用血清胸苷激酶1(STK1)作为筛查肿瘤、癌前病变的广谱肿瘤标志物。方法选取中老年体检人群620例,采用高灵敏度点印染免疫增强发光检测系统,检测血清TK1的浓度,与常规体格检查平行进行,对中老年人肿瘤、癌前病变早期风险进行评估。结果阳性组STK1为(6.72±4.05)pmol/L,高于阴性组(0.86±0.35)pmol/L,差异有统计学意义(P<0.05),STK1检测结果性别比较差异无统计学意义(P>0.05)。STK1阳性病例35例,阳性率5.6%(35/620),阳性组疾病有:恶性肿瘤2例,良性肿瘤18例,癌前病变5例,非肿瘤增殖性疾病5例,其他感染性疾病5例。结论 STK1作为肿瘤标志物检测具有广谱性,可作为肿瘤、癌前病变的普筛;符合检测成本-效果,中老年人需要做全身肿瘤的预测时,可作为价格不算贵且检测方法不复杂(通过血清学检测)的项目。

To Investigate Middle-old Ages Serum Thymidine Kinase 1 on Physical Management Tumor Screening

Objective Observe middle-old age which above 45 years old cases serum thymidine kinase I （STKI）on tumor mass screening. Methods 620 cases on physical examination testing STK1 by using sensitive chemiluminescence＇s dot blot assay. Assess the significance of STK1 in diagnosis and prognosis of cancer. Results Positive group（STK1 value 6.72±4.05pmol/L） was higher than negative group（SYK1 value 0.86±0.35pmol/L） （P〈 0.05）. Both group STK1 value was not significant difference with gender（P〉0.05）. There were 35 positive cases（positive rate 5.6%） including cancer 2 cases, benign tumor 18 cases, pre-malignant tumor 5 cases, nontumor profiferation disease 5 cases and infectious disease 5 cases. Conclusion STK1 can act as general tumor marker on carsinoma mass screening in middle-old ages and fit in with cost-effect because it is not expensive and iust serum testinz.